IPP Bureau
Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide
By IPP Bureau - June 22, 2024
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
Sumitomo Pharma presents new clinical data on DSP-5336 at the European Hematology Association 2024 Congress
By IPP Bureau - June 20, 2024
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Ascentage Pharma aims global license agreement with Takeda for Olverembatinib
By IPP Bureau - June 20, 2024
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
Sensitech acquires Berlinger & Co. Monitoring Solutions to strengthen life sciences cold chain solutions
By IPP Bureau - June 20, 2024
Berlinger brings a suite of proprietary and high-quality hardware and software solutions that broaden Sensitech's end-to-end cold chain monitoring product portfolio
Roche receives FDA clearance on its digital pathology solution for diagnostic use
By IPP Bureau - June 20, 2024
This clearance is a foundational step in Roche's commitment to enable routine clinical diagnosis with its digital pathology solutions
Alembic Pharmaceuticals gets USFDA final approval for Dabigatran Etexilate capsules
By IPP Bureau - June 19, 2024
Dabigatran Etexilate Capsules are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients
.jpg "Cipla EU to invest an additional € 3 million in Ethris")
Cipla EU to invest an additional € 3 million in Ethris
By IPP Bureau - June 19, 2024
Cipla had earlier invested € 15 million in Ethris in 2022
USFDA completes audit of contract manufacturing facility of Jubilant Pharmova Montreal unit
By IPP Bureau - June 19, 2024
The USFDA has issued 15 observations pursuant to the completion of audit. JHSGP will submit an action plan on the observations
FDA approves Lenire device by Neuromod for tinnitus treatment option for US veterans
By IPP Bureau - June 19, 2024
Lenire is the first and only bimodal neuromodulation device to be awarded a Federal Supply Schedule (FSS) Contract from the US Government
Pfizer reports positive results from Echelon-3 study
By IPP Bureau - June 17, 2024
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
Indian medical device industry to touch US$ 50 billion by 2030
By IPP Bureau - June 17, 2024
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Lupin appoints Abdelaziz Toumi as CEO of its API CDMO subsidiary
By IPP Bureau - June 17, 2024
Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,
Health Minister J P Nadda takes review meeting of Department of Pharmaceuticals
By IPP Bureau - June 17, 2024
Department presents a detailed overview of the Pharma and MediTechsector and gives a detailed presentation on the activities of Department
Imfinzi approved in the US for endometrial cancer
By IPP Bureau - June 17, 2024
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
